5467-72-1

Basic information

• Product Name: 2-AMINO-4'-BROMOACETOPHENONE HYDROCHLORIDE
• Synonyms: 2-amino-1-(4-bromophenyl)ethanone hydrochloride;2-Amino-4'-bromoacetophenone HCl;alpha-Amino-p-bromoacetophenone hydrochloride;N-p-Bromophenacylamine hydrochloride;2-Amino-4zzhlxy-bromoacetophenone hydrochloride96%;2-Amino-4'-bromoacetophenone hydrochloride, 2-Amino-1-(4-bromophenyl)ethan-1-one hydrochloride;Ethanone,2-aMino-1-(4-broMophenyl)-, hydrochloride (1:1);2-Amino-4'-bromoacetophenone hydrochloride 96%
• CAS NO: 5467-72-1
• Molecular Formula: C₈H₈BrNO*ClH
• Molecular Weight: 250.52
• EINECS: 226-778-3
• Product Categories: Building Blocks;C7 to C8;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks;C7 to C8;Carbonyl Compounds;Ketones
• Mol File: 5467-72-1.mol

Chemical Properties

• Melting Point: 285 °C (dec.)(lit.)
• Boiling Point: 322.8 °C at 760 mmHg
• Flash Point: 149 °C
• Appearance: /
• Density: 1.52g/cm³
• Vapor Pressure: 0.000272mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• BRN: 3630035
• CAS DataBase Reference: 2-AMINO-4'-BROMOACETOPHENONE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-4'-BROMOACETOPHENONE HYDROCHLORIDE(5467-72-1)
• EPA Substance Registry System: 2-AMINO-4'-BROMOACETOPHENONE HYDROCHLORIDE(5467-72-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• RTECS: AM5840000
• HazardClass: IRRITANT
• Hazardous Substances Data: 5467-72-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2-AMINO-4'-BROMOACETOPHENONE HYDROCHLORIDE is used as a key reagent for the synthesis of Ledipasvir (L320100), a potent, once-daily oral NS5A inhibitor. This medication is specifically designed for the treatment of hepatitis C virus infection, offering an effective therapeutic option for patients.
Additionally, 2-AMINO-4'-BROMOACETOPHENONE HYDROCHLORIDE is utilized in the preparation of β-receptor agonists, such as (-)-Denopamine (D231485) and (-)-Arbutamine (A766300). These compounds have significant applications in the medical field, particularly in the treatment of cardiovascular conditions, as they can stimulate the activity of β-adrenergic receptors, leading to various physiological effects.

InChI:InChI=1/C8H8BrNO/c9-7-3-1-6(2-4-7)8(11)5-10/h1-4H,5,10H2

Upstream product

• 49615-87-4 2-(4-bromophenyl)-2-oxoacetaldehyde oxime 
• 7644-04-4 4-bromophenacylamine 
• 127118-88-1 C₁₀H₈BrNO₃ 
• 6200-09-5 (4-bromo-phenacyl)-hexamethylenetetraminium; bromide 
• 18197-26-7 sodium diformamide 
• 99-73-0 para-bromophenacyl bromide 
• 71559-14-3 2-azido-1-(4-bromophenyl)ethanone 
• 99-90-1 para-bromoacetophenone 

Downstream Products

• 51641-42-0 4-[5-(4-bromo-phenyl)-oxazol-2-yl]-naphthalene-1,8-dicarboxylic acid anhydride 
• 115846-55-4 1-(4-Bromo-phenyl)-2-(4,5-dihydro-3H-pyrrol-2-ylamino)-ethanone; hydrochloride 
• 94993-73-4 5-Methyl-4-nitro-2H-pyrazole-3-carboxylic acid [2-(4-bromo-phenyl)-2-oxo-ethyl]-amide 
• 96907-80-1 N-[2-(4-Bromo-phenyl)-2-oxo-ethyl]-4-methyl-benzamide 
• 96907-75-4 1-(4-nitrophenyl)-4-(4-bromophenyl)-2-aza-1,4-butanedione 
• 76477-12-8 N-(2-(4-bromophenyl)-2-oxoethyl)acetamide 
• 36018-05-0 N,N'-di(p-Bromophenacyl)terephthalamide 
• 55368-57-5 4-bromo-N-[2-(4-bromophenyl)-2-oxoethyl]benzamide 
• 64748-80-7 N-[2-(4-bromo-phenyl)-2-oxo-ethyl]-2-(2,4-dioxo-imidazolidin-1-ylimino)-acetamide 
• 55453-04-8 2-(4-bromo-phenyl)-N-[2-(4-bromo-phenyl)-2-oxo-ethyl]-acetamide 
• 55368-61-1 N-[2-(4-bromo-phenyl)-2-oxo-ethyl]-3-cyano-benzamide 
• 181226-62-0 3-(4'-bromophenyl)-6,7,8,9-tetrahydro-5H-imidazo<1,2-a>azepine 
• 82221-15-6 N-(2-(4-bromophenyl)-2-oxoethyl)benzamide 
• 339185-70-5 1,1-dimethylethyl [2-(4-bromophenyl)-2-oxoethyl]carbamate 

Relevant articles and documents

The reaction of prop-2-ynylsulfonium salts and sulfonyl-protected β-amino ketones to epoxide-fused 2-methylenepyrrolidines and S-containing pyrroles

A novel divergent domino annulation reaction of prop-2-ynylsulfonium salts with sulfonyl-protected β-amino ketones has been developed, affording various epoxide-fused 2-methylenepyrrolidines and S-containing pyrroles in moderate to excellent yields. Prop-2-ynylsulfonium salts act as C2synthons in the reactions providing a promising epoxide-fused skeleton in a single operation with readily accessible starting materials.

A morpholine group containing pyridine and double protonizing site of the pH of the fluorescent probe, preparation method and application (by machine translation)

The invention provides a pH fluorescence probe with double-protonation loci of pyridine and morpholine groups and a preparation method and application thereof. The structure of the probe is as shown in formula (I) in the specification. The probe has relatively wide pH response within a pH range of 3.1-5.0, the pKa of the probe is 4.05, in addition, the probe has relatively good water solubleness, optical and chemical stability and relatively good ion selectivity and biological compatibility. Fluorescence microimaging tests show that the probe has relatively good cell permeability and pH response, and has very small cytotoxicity.

Monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and preparation method

The invention discloses a monoglycosyl-containing heterocyclic compound for inhibiting hepatitis C viruses and a preparation method. The monoglycosyl-containing heterocyclic compound has a chemical structure represented by a formula I shown in the description. The monoglycosyl-containing heterocyclic compound disclosed by the invention can be used for effectively inhibiting protease of the hepatitis C viruses and treating infection of the hepatitis C viruses (HCV).

Bromophenol-oxazole compound and its use in drug for treatment on diabetes mellitus type 2

The invention relates to a chemical total synthesis method of novel bromophenol-oxazole PTP1B and its use in a drug for treatment on diabetes mellitus type 2. The PTP1B inhibitor has a structural formula shown in the description. The compound improves insulin receptor sensibility through inhibiting the activity of protein tyrosine phosphatase 1B and has good treatment effects on insulin resistance-type diabetes mellitus type 2.

PH fluorescent probe by taking pyridine as protonizing site and application thereof

The invention relates to the technical field of detection, and particularly relates to a novel compound by using 4-(5-phenyl-2-oxazolyl)pyridine as a kernel structure as shown in the general formula (I), as well as a chemical preparation process of the pH fluorescent probe. According to the compound, R1, R2 and R3 are halogen atoms, nitrogen atoms, alkyl, alkoxy or group as shown in the formula IA, wherein Y is a group formed by covalent linkage of methylene, oxygen atom or nitrogen atom with a group as shown in a formula IB (in the formula IB, R5 is hydrogen atom, alkyl or alkoxy, Z1, Z2 and Z3 are null or oxygen atoms, and n, o and p are 0, 1 or 2; R4 represents hydrogen atom, methyl, methoxyl or a group as shown in the formula IB, and m is 0, 1 or 2; R1, R2 and R3 are not halogen atom, hydrogen atom, alkyl or alkoxy at the same time, and X is CH=CH or null, namely a biphenyl structure. The chemical preparation process is applied to fluorescent probe detection on pH value in an aqueous solution, fluorescent probe detection on the pH value in a cell, especially fluorenscense angiography of cells.

NOVEL HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

CHEMICAL COMPOUNDS

Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.

Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents

A new series of aryl substituted imidazol-2-one derivatives structurally related to combretastatin A-4 (CA-4) were synthesized and evaluated for their cytotoxic activities in vitro against various human cancer cell lines including MDR cell line. The cytotoxic effects of compounds 7b and 7i proved to be similar to or greater than that of docetaxel. The highly active compound 7b also exhibited excellent inhibitory activity on tumor growth in vivo.

Asymmetric hydrogenation of α-primary and secondary amino ketones: Efficient asymmetric syntheses of (-)-arbutamine and (-)-denopamine

Two ss-receptor agonists (-)-denopamine and (-)-arbutamine were prepared in good yields and enantioselectivities by asymmetric hydrogenation of unprotected amino ketones for the first time by using Rh catalysts bearing electron-donating phosphine ligands. A series of α-primary and secondary amino ketones were synthesized and hydrogenated to produce various 1,2-amino alcohols in good yields and with good enantioselectivies. This Rh electron-donating phosphine-catalyzed asymmetric hyderogenation repI resents one of the most promising and convenient approaches towards the asymmetric synthesis of chiral amino alcohols.

THIAZOLE BENZENESULFONAMIDES AS BETA3 AGONISTS FOR TREATMENT OF DIABETES AND OBESITY

Thiazole substituted benzenesulfonamides are β 3 adrenergic receptor agonists with very little β 1 and β. sub. 2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.